<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544594</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE MucM001-15</org_study_id>
    <nct_id>NCT02544594</nct_id>
  </id_info>
  <brief_title>Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction</brief_title>
  <acronym>ECLS-SHOCK</acronym>
  <official_title>Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares standard treatment plus Extra-Corporal Life Support (ECLS) versus
      standard treatment alone in patients with cardiogenic shock due to myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiogenic shock is a serious complication of a myocardial infarction. Despite optimal
      treatment the mortality in patients with cardiogenic shock still exceeds 50% and surviving
      patients mostly suffer from severe heart failure due to an impaired cardiac function.

      This study compares standard treatment plus Extra-Corporal Life Support (ECLS) versus
      standard treatment alone in patients with cardiogenic shock due to myocardial infarction.

      The main study hypothesis is to explore if additional treatment with ECLS preserves cardiac
      function (left ventricular ejection fraction) in patients with cardiogenic shock complicating
      acute myocardial infarction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Best medical therapy versus best medical therapy + ECLS in the treatment of cardiogenic shock complicating acute myocardial infarction</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) on day 30</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate levels</measure>
    <time_frame>up to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potentia hydrogenic levels</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term mortality at 12 months</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Outcome (modified Rankin Scale)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE (defined as cardiac death, non-fatal myocardial re-infarction, rehospitalisation for cardiac reasons and the need of CABG or PCI)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Extra-Corporal Life Support (ECLS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment plus Extra-Corporal Life Support (ECLS) (from Sorin) in patients with cardiogenic shock due to myocardial infarction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment alone without Extra-Corporal Life Support (ECLS) in patients with cardiogenic shock due to myocardial infarction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extra-Corporal Life Support (ECLS)</intervention_name>
    <description>Extra-Corporal Life Support (ECLS) (from Sorin)</description>
    <arm_group_label>Extra-Corporal Life Support (ECLS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cardiogenic shock complicating acute myocardial (STEMI or NSTEMI) with

          -  intended revascularization (PCI or CABG)

          -  Systolic blood pressure &lt; 90 mmHg &gt; 30 min or inotropes required to maintain pressure
             &gt; 90 mmHg during systole

          -  Signs of left heart insufficiency and pulmonary congestion

          -  Signs of impaired organ perfusion with at least one of the following:

               -  Altered mental status

               -  Cold, clammy skin

               -  Urine output &lt;30 ml/h

               -  Serum lactate &gt;2mmol/l

          -  Informed consent

        Exclusion Criteria:

          -  Resuscitation &gt; 60 minutes, ischemia &gt; 10 minutes

          -  No intrinsic heart action

          -  Cerebral deficit with fixed dilated pupils

          -  Mechanical infarction complication

          -  Onset of shock &gt; 12 h

          -  Severe peripheral artery disease

          -  Aortic regurgitation &gt; II.Â°

          -  Age &gt; 80 years

          -  shock of other cause

          -  Other severe concomitant disease

          -  participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Brunner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munich University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Massberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Munich University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>PD Dr. Stefan Brunner</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

